2014 · FINDING
CITEDKraus et al. — obese mice
NNMT knockdown in obese mice produced lean-mass-preserving weight loss without caloric restriction.
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
WEIGHT LOSSRESEARCH
5-Amino-1MQ.
An NNMT inhibitor — fat loss without muscle loss
AKA · 5-amino-1-methylquinolinium · NNMT inhibitor
WEIGHT LOSSORAL
A small-molecule NNMT inhibitor (not technically a peptide, but sold alongside). Blocks the enzyme that disposes of methyl groups, which keeps SAM high and biases metabolism toward lean-mass preservation. Research-grade only.
Under investigation
Half-life
2
Citations
1
Routes
1
Categories
63
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
A small-molecule NNMT inhibitor (not technically a peptide, but sold alongside). Blocks the enzyme that disposes of methyl groups, which keeps SAM high and biases metabolism toward lean-mass preservation. Research-grade only.
Blocks an enzyme (NNMT) that slows down fat cell metabolism. When you block it, fat cells burn more, and muscle cells keep their anabolic signaling.
Cycles of 8–12 weeks. Very new; monitor closely.
WHAT IT MIGHT HELP WITH.
1
Fat loss with preserved lean mass (animal models)
2
Oral bioavailability
3
Increased NAD+ levels in treated tissues
4
Improved insulin sensitivity
5
Investigated for sarcopenic obesity
HOW IT WORKS.
§ 02 · MECHANISMBlocks an enzyme (NNMT) that slows down fat cell metabolism. When you block it, fat cells burn more, and muscle cells keep their anabolic signaling.
Selective inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT overexpression in adipose tissue correlates with obesity. Inhibition raises intracellular nicotinamide adenine dinucleotide levels and SAM, stimulating fat-cell energy expenditure and skeletal muscle protein synthesis.
WHO IT'S FOR
- ✓Metabolic research
- ✓Sarcopenic obesity models
WHO SHOULD AVOID
- ✕Pregnancy
- ✕Those without physician oversight
THE RESEARCH.
§ 03 · 2 STUDIES2017 · FINDING
Neelakantan et al. — inhibitor design
Established 5-amino-1MQ as a potent, selective NNMT inhibitor with oral bioavailability.
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Cycles of 8–12 weeks. Very new; monitor closely.
150mg oral daily (reported research range; 50–300mg explored)
FREQUENCY
Most-cited schedule
Once or twice daily
ROUTES
Delivery methods
ORAL
HALF-LIFE
Steady state drives frequency
Under investigation
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using 5-Amino-1MQ should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Oral capsule
- · Oral solution
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
SIDE EFFECTS & RISKS.
§ 06 · SAFETY·
GI upset at higher doses
Occasional · mild
·
Headache
Occasional · mild
!
Unknown long-term human effects
Unknown · serious
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
We tried nine suppliers across 2025 and kept picking PEAK LAB for 5-Amino-1MQ: 99.4% HPLC purity, COA on every batch, cold chain intact. Shop through our link and we earn a small commission — affiliate relationship is disclosed.
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on 5-Amino-1MQ + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.